Related Experiment Video
Updated: May 21, 2026
Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models
Published on: September 6, 2024
Cell-type dependent response of melanoma cells to aloe emodin
J Radovic1, D Maksimovic-Ivanic, G Timotijevic
1Department of Immunology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Bulevar Despota Stefana 142, 11060 Belgrade, Serbia.
Abstract:
Intrinsic characteristics of melanoma cells such as expression of inducible nitric oxide synthase (iNOS), redox status, and activity of signaling pathways involved in proliferation, differentiation and cell death define the response of the cells to the diverse treatments. In this context we compared the effectiveness of herbal antaquinone aloe emodin (AE) against mouse B16 melanoma and human A375, different in initial activity of ERK1/2, constitutive iNOS expression and basal level of reactive oxygen species (ROS). Both cell lines are sensitive to AE treatment. However, while the agent induces differentiation of B16 cells toward melanocytes, in A375 cells promoted massive apoptosis. Differentiation of B16 cells, characterized by enhanced melanin production and tyrosinase activity, was mediated by H(2)O(2) production synchronized with rapid p53 accumulation and enhanced expression of cyclins D1 and D3. Caspase mediated apoptosis triggered in A375 cells was accompanied with Bcl-2 but not iNOS down-regulation. In addition, opposite regulation of Akt-ERK1/2 axis in AE treated B16 and A375 cells correlated with different outcome of the treatment. However, AE in a dose-dependent manner rescued both B16 and A375 cells from doxorubicin- or paclitaxel-induced killing. These data indicate that caution is warranted when AE is administrated to the patients with conventional chemotherapy.
Insights
Aloe emodin (AE) has differential effects on melanoma cells, inducing differentiation in B16 cells and apoptosis in A375 cells. AE also protects melanoma cells from chemotherapy, suggesting caution during combined treatment.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Melanoma cell responses to treatment depend on intrinsic factors like iNOS expression, redox status, and signaling pathways.
- Aloe emodin (AE), a herbal anthraquinone, exhibits varying effects on different cancer cell types.
Purpose of the Study:
- To compare the efficacy of AE on mouse B16 melanoma and human A375 melanoma cells.
- To investigate the distinct cellular mechanisms underlying AE's effects on these two melanoma models.
- To evaluate AE's potential to modulate chemotherapy resistance.
Main Methods:
- Treatment of B16 and A375 melanoma cells with AE.
- Analysis of cell differentiation, apoptosis, reactive oxygen species (ROS) production, and key protein expressions (p53, cyclins, Bcl-2, Akt, ERK1/2).
- Assessment of AE's effect on doxorubicin- or paclitaxel-induced cell death.
Main Results:
- AE induced differentiation in B16 cells (melanin production, tyrosinase activity) via H2O2, p53, and cyclin D1/D3.
- AE triggered caspase-mediated apoptosis in A375 cells, with Bcl-2 down-regulation but not iNOS.
- Opposite regulation of Akt-ERK1/2 pathways was observed in AE-treated B16 and A375 cells.
- AE dose-dependently protected both cell lines from chemotherapy-induced killing.
Conclusions:
- AE exhibits distinct anti-cancer effects on different melanoma cell lines, highlighting cell-type specific responses.
- The Akt-ERK1/2 signaling axis plays a crucial role in mediating AE's differential outcomes.
- AE's ability to confer chemoresistance necessitates caution when co-administered with conventional chemotherapy agents.
